磁共振对比剂的新时代
本文讨论了下一代钆基对比剂(包括高弛豫率与靶向Agent)及锰基对比剂的发展前景,认为钆匹醇和钆夸曲兰可能随时间取代现行大环钆螯合物;同时介绍了两种靶向钆螯合物、两种锰基对比剂,以及线性钆对比剂钆双胺注射后脑内特定亚区高钆浓度的新发现和人工智能在剂量降低与新适应证方面的应用。
要点
- 钆匹醇和钆夸曲兰两种下一代高弛豫率钆化合物可能随时间取代现行大环钆螯合物。
- 注射线性对比剂钆双胺后,脑内具有特殊细胞构筑和功能的特定局限亚区可见高钆浓度。
- 人工智能最可能的应用方向为剂量降低和新临床适应证。
核心结论
- 下一代高弛豫率钆基对比剂钆匹醇和钆夸曲兰很可能随时间取代现行大环钆螯合物,尽管后者已被广泛接受、安全性很高且稳定性高。
- 两种新型靶向钆螯合物看起来很有前景,MT218和ProCA32.collagen有潜力改善癌症检测,后者还有潜力用于胶原疾病。
- 锰基化合物研究在搁置20余年后已产生两种极具临床使用潜力的Agent,其中口服四水氯化锰主要用于肝脏成像,静脉用Mn-PyC3A作为无钆替代品用于替代GBCAs。
研究设计与样本
- 本文为综述,讨论下一代钆基对比剂(高弛豫率Agent和靶向Agent)以及锰基Agent,并述及人工智能的影响。
关键影像表现/征象
- 注射线性Agent钆双胺后,脑内具有特殊细胞构筑和功能的特定局限亚区可见高钆浓度。
临床应用与阅片要点
- 原文指出这些发现为定制功能神经学测试铺平了道路,特别是针对因线性GBCAs在世界许多国家持续广泛使用而处于潜在风险的患者。
- 原文述及人工智能最可能的应用为剂量降低和新临床适应证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Next-generation gadolinium-based contrast agents (GBCAs), including both high relaxivity agents and targeted agents, and manganese-based agents with a high probably of commercial success are discussed in some depth. It is highly likely that gadopiclenol and gadoquatrane, both next-generation high relaxivity gadolinium-based compounds, will come in time to replace the current macrocyclic gadolinium chelates, despite the wide acceptance, very high safety profile, and high stability of the latter group. Current research has also made possible the development of 2 new targeted gadolinium chelates, which look very promising, with the potential to improve cancer detection (for both MT218 and ProCA32.collagen) as well as diseases of collagen (for the latter agent). Further work with manganese-based compounds, a topic left fallow for more than 20 years, has also now produced 2 agents with high potential for clinical use, one (manganese chloride tetrahydrate, administered orally) developed primarily for imaging of the liver and the other (Mn-PyC3A, administered intravenously) as a gadolinium-free replacement for the GBCAs. New detail has recently emerged regarding specific circumscribed subregions of the brain with specialized cytoarchitecture and functions in which high gadolinium concentrations are seen following injection of the linear agent gadodiamide. These findings pave the way for tailored functional neurological testing, specifically in patients at potential risk due to the continued wide use in many countries across the world of the linear GBCAs. The impact of artificial intelligence is also critically discussed, with its most likely applications being dose reduction and new clinical indications.
引用
- Runge VM, Heverhagen JT. A New Era in Magnetic Resonance Contrast Media. Invest Radiol. 2023. PMID: 37862104. doi:10.1097/RLI.0000000000001037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。